Thrombotic Thrombocytopenic Purpura Therapy
Research reports on thrombotic thrombocytopenic purpura therapy from Johann Wolfgang Goethe University, Department of Hematology provide new insights
Published in Biotech Law Weekly, March 23rd, 2007
New research, "Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia," is the subject of a report. According to recent research from Mainz, Germany, "Treatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases."
"Patients with non-familial TTP or AIHA and no...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2007-03-23)
More Articles from Biotech Law Weekly
- Biomedical Engineering
Researchers at University Autonoma of Barcelona have published new data on biomedical engineering - Allergies Vaccines
Scientists at Swiss Institute of Allergy and Asthma Research detail research in allergies vaccines - Angiogenesis
Scientists at Johann Wolfgang Goethe University publish research in angiogenesis - Asthma Therapy
Reports from INSERM add new data to research in asthma therapy - Asthma Therapy
Studies from United BioSource Corporation have provided new data on asthma therapy - Biochemistry
Research findings from China Agricultural University update understanding of biochemistry - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
